
Orthofix International (OFIX) Stock Forecast & Price Target
Orthofix International (OFIX) Analyst Ratings
Bulls say
Orthofix Medical is poised for growth due to its innovative bone growth therapies, spinal implants, biologics, and other cutting-edge technologies. The company's recent strategic realignment of its spine leadership team and strong financials, including a solid Q4 and positive free cash flow for the full year, further demonstrate its potential for success. Despite some challenges, Orthofix's OUTPERFORM investment rating and projected adjusted EBITDA margin show promise for investors in the long-term.
Bears say
Orthofix Medical is a medical device company focused on orthopedics and spine solutions, with the majority of its revenue coming from the global spine segment. The recent fee schedule update for non-invasive bone growth stimulators is expected to have a negative impact on the company's financials and could result in a lower price target, but the company has also taken steps to streamline its operations and affirm its full-year financial guidance. It will be important to closely monitor the company's performance, particularly in the critical U.S. spine and fast-growing U.S. limb reconstruction segments, in the coming quarters. Additionally, while the company has a strong balance sheet and positive free cash flow for the quarter, it will be important to monitor any potential impact on future cash flows due to the fee schedule update.
This aggregate rating is based on analysts' research of Orthofix International and is not a guaranteed prediction by Public.com or investment advice.
Orthofix International (OFIX) Analyst Forecast & Price Prediction
Start investing in Orthofix International (OFIX)
Order type
Buy in
Order amount
Est. shares
0 shares